Side-by-side comparison of AI visibility scores, market position, and capabilities
Roseland NJ payroll and HCM leader (NASDAQ: ADP) $19.2B FY2024 revenue (+7%); 1.1M clients, $55B+ float income, TotalSource PEO, ADP NER economic data competing with Paychex and Workday.
Automatic Data Processing, Inc. (ADP) is a Roseland, New Jersey-based payroll processing and human capital management company — publicly traded on the NASDAQ (NASDAQ: ADP) as an S&P 500 Information Technology component — providing payroll processing, tax administration, benefits administration, HR management, time and attendance, talent management, and retirement plan services to 1.1 million clients ranging from small businesses (1-49 employees) to large enterprises (1,000+ employees) through approximately 58,000 employees globally. In fiscal year 2024 (ending June 2024), ADP reported revenues of $19.2 billion (+7% year-over-year) and adjusted EPS of $9.14 (+12%), continuing the company's consistent mid-to-high single digit revenue growth and double-digit EPS growth from operating leverage and capital return. CEO Maria Black (appointed 2023, ADP's first female CEO, previously leading ADP's employer services division) leads ADP's strategy of deepening client platform engagement: ADP's "employer of record" (EOR) and professional employer organization (PEO — ADP TotalSource) services handle all payroll, HR compliance, and benefits administration for small and mid-size businesses — creating outsourcing relationships where ADP becomes the operational HR department for companies that lack internal HR expertise. ADP's client fund float (ADP holds $55+ billion in client payroll funds between the time employers fund payroll and ADP distributes payments to employees and tax authorities — a multi-day float period generating interest income on $55B at current interest rates) generated $1.6B+ in interest income in FY2024 as rates remained elevated, creating an earnings tailwind that amplifies ADP revenue growth during high-interest rate environments.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.